Zenas BioPharma announced that obexelimab met its primary and all key secondary endpoints in the Phase 3 INDIGO trial for Immunoglobulin G4-Related Disease (IgG4-RD). The drug demonstrated a 56% reduction in flare risk, 65% reduction in glucocorticoid use, and favorable safety profile comparable to placebo. A Biologics License Application (BLA) was submitted to the FDA in May 2026, with results presented at EULAR 2026 Congress and published in the New England Journal of Medicine.

Zenas BioPharma reported Q1 2026 financial results with cash position of $718.5M and extended runway through Q2 2029. The company advanced obexelimab toward FDA/EMA submissions for IgG4-RD treatment, completed enrollment in the Phase 2 SunStone SLE trial with results expected Q4 2026, initiated Phase 1 testing of oral IL-17 inhibitor ZB021, and continued Phase 3 trials for orelabrutinib in multiple sclerosis. R&D expenses increased to $60.4M from $34.9M year-over-year, and net loss widened to $81.0M from $33.6M, primarily due to increased clinical trial and manufacturing costs.

InnoCare Pharma achieved its first annual profit of 644 million yuan in 2025, two years ahead of schedule, driven by dual revenue engines of licensing deals and product sales. The company's main drug Orelabrutinib continues strong momentum with expanded indications, while new products like Tafasitamab and pipeline asset Mesutoclax advance development. Despite significant progress in globalization and a $2 billion partnership with Zenas BioPharma, InnoCare's Hong Kong-listed shares trade at a modest P/S ratio of 14, suggesting potential upside for the maturing biopharma company.

Zenas BioPharma priced a concurrent public offering of $200 million in 2.50% convertible senior notes due 2032 and 5 million shares of common stock at $20 per share, with estimated net proceeds of $287.5 million. The company plans to use proceeds to support the U.S. commercial launch of obexelimab for IgG4-RD treatment and advance its development pipeline including orelabrutinib Phase 3 trials and ZB021 clinical development.

ENAVATE Sciences increased its stake in Zenas BioPharma by 157,800 shares worth $5.19 million, making it the fund's largest holding at 28.08% of AUM. The position grew to $142.30 million by quarter-end, driven by both the purchase and significant stock price appreciation (up 167% year-over-year). The real focus should be on Zenas' pipeline, particularly obexelimab, with a planned FDA BLA submission in Q2 2026 and Phase 2 lupus data expected by year-end.

Pomerantz LLP is investigating potential securities fraud claims against Zenas BioPharma following disappointing Phase 3 trial results for obexelimab in IgG4-RD announced on January 5, 2026. Despite the company characterizing results as 'positive,' analysts noted the drug's efficacy fell short of commercial viability thresholds. The stock declined 51.86% on the announcement and another 8.49% the following day after the CEO acknowledged disappointment with the trial's hazard ratio metric.

Pomerantz LLP announced investigations into securities fraud claims on behalf of investors in three biotech companies. Zenas BioPharma's stock plummeted 51.86% following disappointing Phase 3 trial results for obexelimab, with the CEO acknowledging the drug's efficacy fell short of expectations, triggering an additional 8.49% decline. Similar investigations were initiated for Instil Bio and Corcept Therapeutics.

Leon O. Moulder, CEO of Zenas BioPharma, purchased 36,928 shares through an open-market transaction and announced a licensing deal with InnoCare Pharma for a multiple sclerosis candidate, signaling confidence in the company's potential.

Pomerantz LLP has filed a class action lawsuit against Zenas BioPharma, Inc. (ZBIO) due to potential securities fraud or unlawful business practices. The lawsuit is related to Zenas's initial public offering in September 2024, where the company allegedly misrepresented its ability to fund operations.

Faruqi & Faruqi, LLP is investigating potential claims against Zenas BioPharma, Inc. (ZBIO) for making false and/or misleading statements regarding the company's ability to fund its operations using existing cash and expected net proceeds from the IPO.

A class action lawsuit has been filed against Zenas BioPharma, Inc. alleging that the company's IPO registration statement contained false and/or misleading statements about its ability to fund operations.

Zenas BioPharma, Inc. is facing a class action lawsuit alleging that the company's IPO offering documents were materially false, misleading, or omitted material information by overstating the length of time the company could fund its operations.